This session analyzes the revenue and compliance benefits of the introduction of a 12-month injectable heartworm preventative using data from 4615 general practices in the USA.
Learning Objectives:
To understand the contributions to a 25.7% compliance rate in 4615 representative practices
To provide tools for analyzing revenue driven by adopting an injectable heartworm disease preventative
To discuss ways to improve client education focusing on heartworm disease prevention
.jpg "Christopher Adolph, DVM, MS, ACVM photo")
